Navigation Links
Pharmagen Presents to North Carolina General Assembly at N.C. Bio's Legislative Breakfast

SILVER SPRING, Md., April 4, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen") is excited to announce that it will be presenting its strategic vision on solving the nation's drug shortage crisis to the North Carolina General Assembly at the North Carolina Biosciences Organization (NCBIO) Legislative Breakfast on April 16th.  Each year, NCBIO brings together members of the General Assembly to enjoy breakfast with NCBIO members. This invite-only, legislative event will give Pharmagen the opportunity to meet with State Representatives and State Senators to discuss its planned move to North Carolina.  RTI International and Kymanox – both event sponsors – are North Carolina companies integral to implementing the Pharmagen manufacturing strategy.

About Pharmagen

Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nation's sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions.  Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.


NCBIO is dedicated to promoting the future growth and development of North Carolina's bioscience industry. NCBIO advocates for state and federal public policies that encourage the growth of life science companies, support the development of a strong life science workforce, and promote research and technology transfer at universities and other institutions. The Organization also provides members opportunities to network, collaborate and save money. NCBIO's ultimate goal is to help North Carolina's bioscience community fulfill its extraordinary promise as a source of economic opportunity and improved quality of life for citizens of North Carolina and people around the world.

About RTI International

RTI International is one of the world's leading research institutes, dedicated to improving the human condition by turning knowledge into practice. Our staff of more than 3,700 provides research and technical services to governments and businesses in more than 75 countries in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, international development, economic and social policy, energy and the environment, and laboratory testing and chemical analysis.

About Kymanox

Kymanox, with headquarters now in RTP, NC, is a premier technical products and technical project management company. We are experts in providing our clients in the Biopharmaceutical, Medical Device, and Nanotechnology industries with engineering, scientific, regulatory, and process operations support. Our engineers solve complex scale-up and manufacturing problems and our compliance team ensures products receive FDA and global regulatory approval.  With our competency and focus on commercialization, Kymanox helps bring new products to patients in need.

Contact: 888-264-4597 or

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.  The risks, uncertainties and other factors are more fully discussed in Pharmagen' filings with the U.S. Securities and Exchange Commission.  All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned.

SOURCE Pharmagen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmagen Announces Year-End Financial Results
2. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
3. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
4. Versus Presents New Hand-Hygiene Alliance, Wireless Sensors and RTLS Education at HIMSS13
5. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
6. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
7. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
8. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
9. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
10. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
11. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
Post Your Comments:
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):